Evotec Reports Second Multi-Target Collaboration With UCB

Evotec AG (EVT) entered into a second multi-year, multi-target drug discovery cooperation with UCB SA (UCB) in the field of immunology. Evotec will identfy small molecules against a selected number of targets.

Evotec will receive research funding based on the resource allocated over the projects and will be further rewarded on achieving the goals with early stage discovery, preclinical and clinical milestones. Evotec will also receive royalties based on net sales of any approved drugs.

To contact the editor responsible for this story: Mariajose Vera at mvera1@bloomberg.net

Bloomberg reserves the right to remove comments but is under no obligation to do so, or to explain individual moderation decisions.

Please enable JavaScript to view the comments powered by Disqus.